INTRODUCTION
Welcome to tCR-TIL
The TCR-TIL (Translational Colorectal Research – Tumor Immunology Laboratory) is dedicated to advancing the field of tumor immunology, with a particular focus on patient-derived samples from a range of cancers, including colorectal cancer. Our work combines cutting-edge basic and translational research to develop innovative immunotherapies such as CAR-T and TCR-T cell therapies. These therapies aim to offer new treatment options for patients battling refractory or metastatic cancers—diseases that have proven resistant to conventional therapies. Ultimately, we are committed to improving survival outcomes and enhancing quality of life.
– Our Mission/Vision
Our mission is to push the boundaries of cancer treatment by developing next-generation immunotherapies. By building on a foundation of in-depth tumor immune research and pre-clinical models, we aim to provide more effective, targeted therapies for patients facing advanced or resistant cancers. Through this, we seek to improve not only survival rates but also the overall quality of life for these patients.
– Research Focus
We specialize in tumor immunology, using patient-derived samples to explore a wide range of data: immunological, genomic, transcriptomic, spatial, and functional. By analyzing these factors, we aim to develop and refine therapies, including CAR-T and TCR-T, to create more effective treatment options for patients with metastatic and refractory cancers.
PUBLISHED RESEARCH
Our research is detailed in these publications.
antitumor immunity study
The 2022 study published in the journal Science Immunology is an antitumor immunity study that discovered CD39+ tissue-resident memory CD8+ T cells (TRM) play a key role in antitumor immunity in breast cancer.These cells, found in both tumors and metastatic lymph nodes, show clonal overlap with blood effector memory T cells, suggesting their importance in a systemic immune response. Additionally, we identified that these CD39+ TRM cells can be reinvigorated with immune checkpoint inhibitors, highlighting their potential role in enhancing the efficacy of immunotherapy.
T cell immunity study
The 2022 study published in the journal Nature Communications is a T cell immunity study that found SARS-CoV-2-specific T cell memory lasts at least 10 months post-recovery, independent of disease severityWe identified that these memory T cells retain anti-viral function, polyfunctionality, and the generation of a stem cell-like subset. This study utilized various immunological techniques, highlighting our lab’s expertise in exploring immune protection mechanisms during inflammation.